How will you utilize newly FDA approved anifrolumab for SLE in your practice?

This question is part of a collaboration with RheumMadness and is specifically in reference to: Long-term outcomes of anifrolumab in SLE

Answer from: at Community Practice

The answer to this SLE question involves a complex decision-making process. It is such an important question! I apologize in advance for the long answer. I am in the camp of achieving remission in my SLE patients and getting them off prednisone in the safest ways possible (Fanouriakis et al., P...

Comments

at Marian Regional Medical Center
Would one consider adding anifrolumab as a 3rd age...

at Uniformed Services University of the Health Sciences (USUHS)
Dr. @Frank Scott: Since there have been no clinica...

at Marian Regional Medical Center
Thanks @Donald E. Thomas!!!

Answer from: at Academic Institution

I think of anifrolumab particularly for patients with cutaneous disease. The TULIP-2 trial showed promise for anifrolumab in these patients as a secondary endpoint. In patients with at least moderately active skin disease, 49% of patients achieved >= 50% reduction in CLASI compared to 25% in the ...

Please select the option that best describes you:

How will you utilize newly FDA approved anifrolumab for SLE in your practice?

Related Questions